Letteratura scientifica selezionata sul tema "Prognostic markers"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Prognostic markers".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Prognostic markers"
Kovaleva, Olga V., Madina A. Rashidova, Daria V. Samoilova, Polina A. Podlesnaya, Rasul M. Tabiev, Valeria V. Mochalnikova e Alexei Gratchev. "CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 22, n. 1 (5 gennaio 2021): 450. http://dx.doi.org/10.3390/ijms22010450.
Testo completoTaha, Anas, Stephanie Taha-Mehlitz, Stephanie Petzold, Sergey L. Achinovich, Dmitry Zinovkin, Bassey Enodien, Md Zahidul I. Pranjol e Eldar A. Nadyrov. "Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer". Molecules 27, n. 3 (18 gennaio 2022): 596. http://dx.doi.org/10.3390/molecules27030596.
Testo completoElias, Jules M. "The Prognosis of Prognostic Markers. Quo Vadis?" Journal of Histotechnology 19, n. 1 (marzo 1996): 7–8. http://dx.doi.org/10.1179/his.1996.19.1.7.
Testo completoVeryaskina, Yuliya Andreevna, Sergei Evgenievich Titov, Igor Borisovich Kovynev, Tatiana Ivanovna Pospelova e Igor Fyodorovich Zhimulev. "Prognostic Markers of Myelodysplastic Syndromes". Medicina 56, n. 8 (27 luglio 2020): 376. http://dx.doi.org/10.3390/medicina56080376.
Testo completoChen, LangXiong, XiaoSong He, ShiJiang Yi, GuanCheng Liu, Yi Liu e YueFu Ling. "Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma". BioMed Research International 2021 (10 febbraio 2021): 1–13. http://dx.doi.org/10.1155/2021/8824195.
Testo completoAlieva, A. M., A. V. Sozykin, N. V. Teplova, E. V. Reznik, D. V. Izimarieva, N. A. Novikova, I. V. Lozovsky, Е. E. Averin, R. K. Valiev e I. G. Nikitin. "Tenascin-C as a cardiovascular marker". Russian Journal of Cardiology 27, n. 8 (3 settembre 2022): 5150. http://dx.doi.org/10.15829/1560-4071-2022-5150.
Testo completoLabussiere, Marianne, Xiao-Wei Wang, Ahmed Idbaih, François Ducray e Marc Sanson. "Prognostic markers in gliomas". Future Oncology 6, n. 5 (maggio 2010): 733–39. http://dx.doi.org/10.2217/fon.10.25.
Testo completoPerkins, Geraldine, Pierre Laurent-Puig e Julien Taieb. "Ampullary carcinoma prognostic markers". Oncotarget 10, n. 44 (16 luglio 2019): 4509–10. http://dx.doi.org/10.18632/oncotarget.27067.
Testo completoBakhshi, Sameer, e Venkatraman Radhakrishnan. "Prognostic markers in osteosarcoma". Expert Review of Anticancer Therapy 10, n. 2 (febbraio 2010): 271–87. http://dx.doi.org/10.1586/era.09.186.
Testo completoRoss, Jeffrey S., Christine E. Sheehan, Hugh AG Fisher, Ronald A. Kauffman, Eric M. Dolen e Bhaskar VS Kallakury. "Prognostic markers inprostate cancer". Expert Review of Molecular Diagnostics 2, n. 2 (marzo 2002): 129–42. http://dx.doi.org/10.1586/14737159.2.2.129.
Testo completoTesi sul tema "Prognostic markers"
Oguejiofor, Kenneth Kenechukwu. "Prognostic markers in oropharyngeal cancers". Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/prognostic-markers-in-oropharyngeal-cancers(fda96224-657d-4049-ae6c-50db33a5388a).html.
Testo completoBlonski, Katharina. "Glycoconjugates as prognostic markers in ovarian cancer". [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=975965115.
Testo completoSalih, Tamir. "Prognostic and predictive markers in oesophageal cancer". Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/15196/.
Testo completoDouglas, Catriona Mairi. "Prognostic markers in head and neck cancer". Thesis, University of Manchester, 2011. http://www.manchester.ac.uk/escholar/uk-ac-man-scw:130436.
Testo completoLaird, Alexander. "Molecular prognostic markers in renal cell carcinoma". Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/17873.
Testo completoSevov, Marie. "RNA-based Prognostic Markers in Chronic Lymphocytic Leukemia". Doctoral thesis, Uppsala universitet, Institutionen för genetik och patologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-133250.
Testo completoWhiteside, Michael C. R. "Genetic markers for prognostic prediction in colorectal cancer". Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.387972.
Testo completoKawesha, Anthony. "Prognostic molecular markers in resected ductal pancreatic carcinoma". Thesis, University of Birmingham, 2017. http://etheses.bham.ac.uk//id/eprint/7596/.
Testo completoMartins, Ana Teresa Pinto Teixeira. ""Prognostic Value Of Methilation Markers In Breast Cancer"". Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/20022.
Testo completoBur, H. (Hamid). "Biological prognostic and predictive markers in Hodgkin lymphoma". Doctoral thesis, Oulun yliopisto, 2018. http://urn.fi/urn:isbn:9789526219455.
Testo completoTiivistelmä Hodgkinin lymfooma (engl. HL) kuuluu heterogeeniseen imukudossyöpien eli lymfoomen ryhmään. Yli 80 % lymfoomapotilaista voidaan parantaa solunsalpaaja- ja sädehoidon avulla. Hyvän ennusteen takia HL- tutkimuksen tärkeä painopiste on säde- ja solunsalpaajahoidon pitkän ajan haittavaikutukset. Huomattava määrä potilaista kärsii tai jopa kuolee hoitoon liittyvistä pitkäaikaishaitoista johtuen. Tämän tutkimuksen tarkoituksena oli löytää uusia mahdollisia biologisia tekijöitä, jotka ennakoisivat taudin huonoa ennustetta ja samalla antaa uusia näkökulmia HL potilaiden hoidon yksilöllistämiseen. Tämä retrospektiivinen tutkimus käsitti vuosina 1997-2015 samanlaisesti hoidettuja Hodgkinin lymfooma -potilaita. Immunohistokemiallisilla värjäyksillä määritettiin biologisten merkkiaineiden, mukaan lukien oksidatiivisen stressin markkereiden 8- hydroksideoksiguanosiinin (8-OHdG) ja nitrotyrosiinin, sekä antioksidanttientsyymien mangaanisuperoksidi-dismutaasin (MnSOD) sekä peroksiredoksiinien (Prx II, Prx III, Prx V, Prx VI) ilmentymistä HL -potilasnäytteissä. Määrittelimme myös immunohistokemiallisilla värjäyksillä epigeneettisten säätelijöiden lysiinin spesifisen demetylaasientsyymin 4 (KDM4A, KDM4B, KDM4D) sekä sirtuiinien (SIRT1, SIRT4, SIRT6), hypoksiaa indusoivien tekijöiden (HIF-1α, HIF-2α), prolyylihydroksylaasientsyymien (PHD1, PHD2, PHD3) ja DNA:ta korjaavien proteiinien Rap1 vaikuttuvan tekijä 1 (Rif1) ja O6-metyyliguaniini-DNA metyylitransferaasin (MGMT) ilmentymistä edustavissa klassista Hodgkinin lymfoomaa sairastavien potilaiden (engl. cHL) näytteissä. Heikko 8-OHdG värjäytyminen ennusti ennenaikaista taudin uusiutumaa levinneessä HL:ssa ja korkea MnSOD ilmaantuvuus ennusti ennenaikaista taudin uusiutumaa koko HL -ryhmässä. Sädehoidetuilla cHL potilailla voimakas PHD1, KDM4B ja KDM4D värjäytyminen ennusti ennenaikaista taudin uusiutumaa. Tulokset osoittivat myös, että erityisesti sädehoidetuilla levinneen taudin cHL potilailla voimakas HIF-1α, SIRT6, Rif1 ja SIRT6 yhdessä Rif1:n kanssa oli yhteydessä pidentyneeseen uusiutumavapaaseen aikaan. Monimuuttuja-analyysissä PHD1, MnSOD, 8-OHdG ja Rif1 itsenäisenä ja yhdessä SIRT6 kanssa ennustivat tilastollisesti merkitsevästi taudin ennenaikaista uusiutumaa. Tulokset osoittavat näiden eri biomarkkereiden merkittävyyden HL:ssä, erityisesti sädehoitoa saaneilla potilailla. Tuloksista voi olla hyötyä, kun hoitokäytäntöjä yksilöidään, mikä voisi helpottaa välttämään liiallista hoitoa ja hallitsemaan pitkäaikaisiin hoitoihin liittyviä haittoja. Näiden alustavien havaintojen vahvistamiseksi tarvitaan kuitenkin lisätutkimuksia
Libri sul tema "Prognostic markers"
CNS cancer: Models, markers, prognostic factors, targets, and therapeutic approaches. Central nervous system cancer: Humana Press, 2009.
Cerca il testo completoDiagnostic and prognostic biomarkers and therapeutic targets in melanoma. Totowa, N.J: Humana, 2012.
Cerca il testo completoMcNamara, M. Morphologic and molecular markers of prognosis in ocular melanoma. Dublin: University College Dublin, 1997.
Cerca il testo completoHughes, Mark D. Point-of-care testing: Status and prognosis. Waltham, MA: Decision Resources, 1996.
Cerca il testo completoLeckey, Joan Lesley. Urinary and tumour markers of disease recurrence and prognosis in transitional cell carcinoma of the bladder. [s.l: The Author], 1997.
Cerca il testo completoGiampietro, Gasparini, e Hayes Daniel 1951-, a cura di. Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect. Totowa, N.J: Humana Press, 2006.
Cerca il testo completoInternational Falk Workshop (1995 Basel, Switzerland). Surrogate markers to assess efficacy of treatmentin chronic liver diseases: Proceedings of the International Falk Workshop held in Basel, Switzerland, October 23-24, 1995. Dordrecht: Kluwer Academic, 1996.
Cerca il testo completoPrognostic Markers in Hematologic Oncology. Informa Healthcare, 2005.
Cerca il testo completoNew Prognostic and Predictive Markers in Cancer Progression. MDPI, 2021. http://dx.doi.org/10.3390/books978-3-03943-978-2.
Testo completoLau, Suzanne Kit-Yan. Validation of putative prognostic markers for non-small cell lung carcinoma. 2007.
Cerca il testo completoCapitoli di libri sul tema "Prognostic markers"
Bahler, David. "Prognostic Markers". In Molecular Pathology Library, 65–72. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-5698-9_3.
Testo completoSchuh, Anna. "Prognostic Markers". In Hematologic Malignancies, 53–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-11392-6_4.
Testo completoSienko, Anna, Timothy Craig Allen e Philip T. Cagle. "Prognostic Markers". In Molecular Pathology Library, 193–99. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-72430-0_18.
Testo completoRhodes, A., P. J. Newman e E. D. Bennett. "Prognostic Markers in Sepsis". In Yearbook of Intensive Care and Emergency Medicine, 238–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72038-3_21.
Testo completoHabuchi, Tomonori. "Prognostic Markers for Bladder Cancer". In Bladder Tumors:, 139–63. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-928-4_8.
Testo completoGarcia, Agustin A., e Nazish Ahmad. "Prognostic Markers in Breast Cancer". In Biomarkers in Oncology, 25–42. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_2.
Testo completoDavies, Janine M., e Howard L. McLeod. "Prognostic Markers in Colon Cancer". In Biomarkers in Oncology, 131–62. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_7.
Testo completoSelvi, Radhakrishna. "Breast Pathology: Conventional Prognostic Markers". In Breast Diseases, 229–31. New Delhi: Springer India, 2014. http://dx.doi.org/10.1007/978-81-322-2077-0_25.
Testo completoGlimelius, Bengt. "Prognostic factors including clinical markers". In Cancer Treatment and Research, 89–96. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1739-5_6.
Testo completoChristenson, Robert H., e Hassan M. E. Azzazy. "Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers". In Cardiac Markers, 59–86. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-385-9_4.
Testo completoAtti di convegni sul tema "Prognostic markers"
Pinho, Rafaela Seixas, Afonso Moraes Melo Junior, Rafael Silva Lemos, Amanda da Silva Furtado e Luís Eduardo Werneck de Carvalho. "Gliomas: tumor markers and prognosis". In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.538.
Testo completo"Rational Identification of Prognostic Markers of Breast Cancer". In International Conference on Bioinformatics Models, Methods and Algorithms. SCITEPRESS - Science and and Technology Publications, 2014. http://dx.doi.org/10.5220/0004915202650270.
Testo completoWilliams, Jennie L., e Ping Ji. "Abstract A54: miRNA profiling: prognostic markers in chemoprevention". In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 30-Oct 3, 2010; Miami, FL. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1055-9965.disp-10-a54.
Testo completoRoth, S., R. M'pembele, A. Stroda, C. Jansen, G. Lurati Buse, I. Tudorache, U. Boeken et al. "New Prognostic Markers for Patients Undergoing VA-ECMO". In 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742846.
Testo completoLima, Beatriz Alves, Andressa da Silva Pereira, Bruna Alves Lima, Diana Gonçalves Lima, Leonardo Ferreira Pucci, Renato Moraes Ferreira, Tiago Castro Ferreira e Henrique Ferreira Pucci. "PREDICTORS OF BREAST CANCER PROGNOSIS BASED ON TUMOR BIOMARKERS". In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2022.
Testo completoFoerster, Y., M. Diensthuber, S. Balster, J. Gabrielpillai, H. Petzold, J. Wagenblast, T. Stöver e C. Geißler. "Neurotrophin receptors - prognostic markers and therapeutic targets for HNSCC?" In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710952.
Testo completoGeißler, C., Y. Foerster, M. Diensthuber, J. Wagenblast, S. Balster, J. Gabrielpillai, H. Petzold e T. Stöver. "Neurotrophin receptors- prognostic markers and therapeutic targets for HNSCC?" In 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727956.
Testo completoAchaiah, Andrew, Andrea Pereira, Harriet Bothwell, Kritica Dwivedi, Armila Rathnapala, Rosia Barker, Valentina Iotchkova, Rachel Hoyles e Ling-Pei Ho. "Blood leukocyte levels as potential prognostic markers in IPF". In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa388.
Testo completoKujawa, Katarzyna A., Ewa Zembala-Nożyńska, Alexander J. Cortez, Jolanta Kupryjańczyk e Katarzyna M. Lisowska. "423 Fibronectin and periostin as prognostic markers in ovarian cancer". In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.136.
Testo completoStetson, Lindsay C., Quinn T. Ostrom, Peter Liao, Andrew E. Sloan, Mark R. Chance e Jill S. Barnholtz-Sloan. "Abstract 4220: Heterogeneous distribution of prognostic protein markers in glioblastoma". In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4220.
Testo completoRapporti di organizzazioni sul tema "Prognostic markers"
Lapointe, Jacques. Identification of Prostate Cancer Prognostic Markers. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2013. http://dx.doi.org/10.21236/ada595253.
Testo completoGullapalli, Rao P. Investigation of Prognostic Ability of Novel Imaging Markers for Traumatic Brain Injury (TBI). Fort Belvoir, VA: Defense Technical Information Center, ottobre 2011. http://dx.doi.org/10.21236/ada577060.
Testo completoGilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediate as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, maggio 2002. http://dx.doi.org/10.21236/ada407363.
Testo completoGilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediates as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, maggio 2004. http://dx.doi.org/10.21236/ada425749.
Testo completoKeyomarsi, Khandan. Cyclin E, A Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, ottobre 1998. http://dx.doi.org/10.21236/ada368551.
Testo completoKeyomarsi, Khandan. Cyclin E, a Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, ottobre 1997. http://dx.doi.org/10.21236/ada341275.
Testo completoBaylin, Stephen B. Hypermethylation of AP-2Alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, maggio 2008. http://dx.doi.org/10.21236/ada494142.
Testo completoBaylin, Stephen. Hypermethylation of AP-2alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, maggio 2006. http://dx.doi.org/10.21236/ada456138.
Testo completoPettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, settembre 1995. http://dx.doi.org/10.21236/ada306440.
Testo completoPettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, settembre 1999. http://dx.doi.org/10.21236/ada382780.
Testo completo